Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 51–100 of 196 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT04752358	ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric…	Phase 2	terminated	Feb 12, 2021	Adaptimmune	Study was terminated due to difficulty recruiting subjects and lack of efficacy	Efficacy / futility
NCT05898828	Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With…	Phase 1 / Phase 2	withdrawn	Jun 12, 2023	National Cancer Institute (NCI)	No enrollment	Enrollment / accrual
NCT04072393	Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers	N/A	terminated	Aug 28, 2019	Washington University School of Medicine	Futility	Efficacy / futility
NCT03621982	Study of ADCT-301 in Patients With Selected Advanced Solid Tumors	Phase 1	terminated	Aug 9, 2018	ADC Therapeutics S.A.	Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.…	Other (stated, no rule matched)
NCT05471401	GI Organ Tracking Via Balloon Applicators	N/A	withdrawn	Jul 22, 2022	Washington University School of Medicine	Low accrual	Enrollment / accrual
NCT05553795	Drainless Robot-assisted Minimally Invasive Esophagectomy(RESPECT)	N/A	terminated	Sep 23, 2022	Technische Universität Dresden	Following a safety analysis and assessment of the complications encountered by external experts, it…	Safety / toxicity
NCT03840967	A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated…	Phase 2	terminated	Feb 15, 2019	Shadia Jalal, MD	Due to slow accruals	Enrollment / accrual
NCT03558724	Fluorescence Endoscopy of Esophageal Carcinoma(ORCA)	Phase 1	terminated	Jun 15, 2018	University Medical Center Groningen	Dose-escalation was finished, but no clear correlation between fluorescence and tumor grade was…	Other (stated, no rule matched)
NCT04272268	Feasibility and Safety of Using Nasal High Flow Oxygen Postoperatively to Reduce…(Hi-FLO)	—	withdrawn	Feb 17, 2020	University Hospitals of North Midlands NHS Trust	Covid-19	COVID-19 / pandemic
NCT03377660	Resection of the Esophagus and Subsequent Weight Loss(REWARD)	—	terminated	Dec 19, 2017	Imperial College London	Funding stopped.	Funding
NCT03108885	Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker…	—	terminated	Apr 11, 2017	Mayo Clinic	Study's Principal Investigator no longer at the institution.	Investigator
NCT06317272	BReath Hold TecHniquEs for Radiotherapy of Esophageal Carcinoma(BROTHER)	N/A	terminated	Mar 19, 2024	University Medical Center Groningen	Poor inclusion	Other (stated, no rule matched)
NCT04244552	A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies	Phase 1	terminated	Jan 28, 2020	Atreca, Inc.	Sponsor Decision	Sponsor / business decision
NCT04187872	LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH)	Phase 1	terminated	Dec 5, 2019	University of Florida	Sponsor terminated	Other (stated, no rule matched)
NCT05579444	Systems Biology of Gastrointestinal and Related Diseases	—	terminated	Oct 13, 2022	Viome	Lack of enrollment.	Enrollment / accrual
NCT02146508	Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital(EXPECT)	N/A	suspended	May 23, 2014	Tenwek Hospital	Medtronic owns Covidien \& closed study 11/18/15. Will reapply through Medtronic.	COVID-19 / pandemic
NCT02017366	Design of the EFECTS Trial(EFECTS)	N/A	withdrawn	Dec 20, 2013	University Hospital, Gasthuisberg	adapted protocol with changed outcome measures, changed recruitment number, no submission to…	Enrollment / accrual
NCT04835987	Evaluation of the Autonomic Nervous System in Patients Undergoing Esophagectomy for Cancer(PROSNACO)	—	withdrawn	Apr 8, 2021	Centre Hospitalier Universitaire de Saint Etienne	Due to a lack of staff in the department, no inclusion could be realized.	Other (stated, no rule matched)
NCT01307956	Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or…	Phase 2	terminated	Mar 3, 2011	University of Nebraska	Drug manufacturer - Amgen requested study stop, per DSMB observation in POWER trial	Drug supply
NCT01366833	Optimal Management of Malignant Dysphagia	N/A	terminated	Jun 6, 2011	McGill University Health Centre/Research Institute of the McGill University Health Centre	Low accrual	Enrollment / accrual
NCT02716688	S-1 and Radiotherapy for Elderly Esophageal Cancer Patients	Phase 2	withdrawn	Mar 23, 2016	Zhejiang Provincial People's Hospital	No patients enrolled.	Enrollment / accrual
NCT03991104	SOX-based CRT for Esophageal Cancer.	Phase 1 / Phase 2	withdrawn	Jun 19, 2019	Zhejiang Provincial People's Hospital	No eligible patients enrolled. We have to withdraw the trial.	Enrollment / accrual
NCT04424641	A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid…	Phase 1 / Phase 2	terminated	Jun 11, 2020	Genmab	Study was terminated due to MTD was reached	Other (stated, no rule matched)
NCT02530437	Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With…	Phase 1 / Phase 2	terminated	Aug 21, 2015	M.D. Anderson Cancer Center	The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was…	Sponsor / business decision
NCT00551759	Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and…	Phase 2	terminated	Oct 31, 2007	Eastern Cooperative Oncology Group	The study used a two-stage design. After stage one, the study was terminated due to excess toxicity.	Safety / toxicity
NCT03233724	Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated…	Phase 1 / Phase 2	terminated	Jul 31, 2017	National Cancer Institute (NCI)	Study terminated due to drug supply issues.	Drug supply
NCT02344810	C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating…	Phase 1 / Phase 2	withdrawn	Jan 26, 2015	Eastern Cooperative Oncology Group	The study did not open to accrual. No start date and no completion dates.	Enrollment / accrual
NCT03385343	Staging of Superficial EAC Using VLE	N/A	terminated	Dec 28, 2017	Mayo Clinic	Device company went out of business	Sponsor / business decision
NCT03240679	Endoscopic Mucosal Resection and Cellular Matrix	N/A	terminated	Aug 7, 2017	Mayo Clinic	Difficulty obtaining investigational product and study support.	Other (stated, no rule matched)
NCT03251417	Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal…	Phase 2	terminated	Aug 16, 2017	Peking University	Because PD-1 antibodies had been proved to be a standard second-line treatment in esophageal…	Other (stated, no rule matched)
NCT04510285	A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+…	Phase 2	terminated	Aug 12, 2020	Memorial Sloan Kettering Cancer Center	Lack of accrual	Enrollment / accrual
NCT04077372	Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal…	N/A	terminated	Sep 4, 2019	Stanford University	Covid-19	COVID-19 / pandemic
NCT03982173	Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA)	Phase 2	withdrawn	Jun 11, 2019	Gustave Roussy, Cancer Campus, Grand Paris	Similar clinical trials showed not very encouraging results, which made us decide, after several…	Other (stated, no rule matched)
NCT03570996	A Trial Comparing Transversus Abdominis Plane Catheter Versus Epidural After Esophagectomy	N/A	terminated	Jun 27, 2018	Swedish Medical Center	COVID 19	COVID-19 / pandemic
NCT04642690	Nitrates and IL-8 in Barrett's Esophagus	—	terminated	Nov 24, 2020	Mayo Clinic	could not collect adequate samples	Other (stated, no rule matched)
NCT05245760	ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer(CRATER)	Phase 2	withdrawn	Feb 18, 2022	Zhonglin Hao	Funding unavailable.	Funding
NCT04060342	GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With…	Phase 1	terminated	Aug 19, 2019	GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.	No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab.	Other (stated, no rule matched)
NCT00573131	Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in…	Phase 2	terminated	Dec 13, 2007	Boston Scientific Corporation	OncoGel did not show any impact on overall tumor response	Other (stated, no rule matched)
NCT04625543	Neoadjuvant Immunotherapy to ESCC	Phase 2	withdrawn	Nov 12, 2020	Qilu Hospital of Shandong University	insufficient money	Other (stated, no rule matched)
NCT03278626	Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma	Phase 1 / Phase 2	terminated	Sep 11, 2017	NYU Langone Health	The study was stopped earlier than anticipated due to slow accrual	Enrollment / accrual
NCT03592407	Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III…	Phase 2	withdrawn	Jul 19, 2018	City of Hope Medical Center	Safety concerns	Safety / toxicity
NCT01868139	Spray Cryotherapy for Esophageal Cancer (ICE-CANCER)(ICE-CANCER)	N/A	terminated	Jun 4, 2013	University of Maryland, Baltimore	insufficient accrual	Enrollment / accrual
NCT01445327	Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With…	—	terminated	Oct 3, 2011	National Cancer Institute (NCI)	Slow, insufficient accrual.	Enrollment / accrual
NCT04520867	STRENGTH Expansion	—	withdrawn	Aug 20, 2020	University of Colorado, Denver	PI is leaving the institution	Other (stated, no rule matched)
NCT05001360	Study of FMT Combined With Nivolumab in Gastric Cancer	N/A	withdrawn	Aug 11, 2021	Fujian Cancer Hospital	We could not get the IRB approval.	Other (stated, no rule matched)
NCT01806649	BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy	Phase 2	terminated	Mar 7, 2013	Prince of Songkla University	Sponsor terminated to continue any clinical trials with study drug	Other (stated, no rule matched)
NCT02857218	Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC…	Early Phase 1	withdrawn	Aug 5, 2016	OHSU Knight Cancer Institute	Inadequate enrollment	Enrollment / accrual
NCT00003487	Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus	Phase 2	terminated	Jan 27, 2003	Burzynski Research Institute	Slow accrual	Enrollment / accrual
NCT04464967	Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in…	Phase 1 / Phase 2	withdrawn	Jul 9, 2020	NKGen Biotech, Inc.	Trial not initiated	Other (stated, no rule matched)
NCT02326779	Low-dose Aspirin Therapy for Esophageal Cancer	Phase 3	withdrawn	Dec 29, 2014	Zhejiang University	The study could not be performed.	Other (stated, no rule matched)

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 23 days agoSource updated Sep 4, 2024source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules